Lobbying Filing Details

Total Spending

$440,000

Activities

2

Lobbyists

2

Gov't Entities

4

Filing Information
Filing UUID:
8c2c5e3e-9704-400f-88a0-51eb9f9d7503
Type:
Q1 - 1st Quarter - Report
Period:
2015 - 1st Quarter (Jan 1 - Mar 31)
Date Posted:
April 20, 2015 at 10:25 PM
Income:
$0
Expenses:
$440,000
Expense Method:
Method A - Reporting amounts using LDA definitions only
Document URL:
View Submission
Quick Info
  • Document Type: text/html
  • Posted By: Mary-Lacey Reuther
Registrant
ASTELLAS PHARMA US, INC.

Pharmaceuticals

Northbrook, Illinois
Client
ASTELLAS PHARMA US, INC.
Illinois, United States of America
Lobbying Activities (2)
Activity 1
Health Issues

Issues related to the implementation of healthcare reform (P.L.111-148, P.L.111-152); Cancer Drug Coverage Parity Act (H.R.1801, S.1879).

Foreign Entity Issues: Astellas Pharma, Inc. based in Tokyo, Japan and as identified in our Lobbying Registration, has an interest as a pharmaceutical company in all of the issues with respect to which Astellas Pharma US has lobbied and listed above.

Lobbyists (2)
  • MRS. MARY LACEY REUTHER
  • MS. MELISSA WIER BANASHAK
Government Entities (2)
  • SENATE
  • HOUSE OF REPRESENTATIVES
Activity 2
Medicare/Medicaid

Issues related to the implementation of health care reform (P.L.111-148, P.L.111-152); Issues related to the Medicare hospital outpatient issues (H.R.4857, S.2980); Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms Act of 2014 (DISARM) (H.R.4187)

Foreign Entity Issues: Astellas Pharma, Inc. based in Tokyo, Japan and as identified in our Lobbying Registration, has an interest as a pharmaceutical company in all of the issues with respect to which Astellas Pharma US has lobbied and listed above.

Lobbyists (2)
  • MRS. MARY LACEY REUTHER
  • MS. MELISSA WIER BANASHAK
Government Entities (2)
  • SENATE
  • HOUSE OF REPRESENTATIVES

Source: LDA.gov, data retrieved November 9, 2026. FilingExplorer is not affiliated with LDA.gov; the Senate Office of Public Records cannot vouch for data or analyses derived from these records after retrieval.